Ziopharm receives Nasdaq approval for capital market listing

By Elaine Rigoli

Tampa, Fla., Sept. 20 - Ziopharm Oncology, Inc. said it received approval of its application to list its common shares on the Nasdaq Capital Market.

The New York-based biopharmaceutical company's common shares will begin trading on Nasdaq on Friday under the symbol ZIOP. The trading of the company's shares on the OTC Bulletin Board will cease on the close of business on Thursday, according to a company news release.

"Obtaining a Nasdaq Capital Market listing is an important step forward in the company's development. We are excited about this milestone and believe that a Nasdaq listing will benefit current and future shareholders by increasing the company's visibility and access in the investment community and helping to generate demand for our stock," chief executive officer Jon Lewis said in the release.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.